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The C. neoformans H99 reference sequence was accessed through the Fungal 
Genome Initiative database at the MIT Broad Institute 
(http://www.broadinstitute.org/annotation/genome/cryptococcus_neoformans/MultiHome
.html) and cryptococcal genomic DNA was isolated as described1. For gene deletion a 
split-marker approach2 with biolistic transformation3 was used to replace specific 
genomic targets with either a nourseothricin (NAT) or geneticin (G418) resistance 
marker as in reference4; a similar strategy was used for complementation at the original 
locus (as in reference5) and for promoter replacement. For over-expression, the ACT 
promoter (as in reference6) was inserted immediately upstream of the USV101 or UXS1 
coding sequences, preceded by the NAT resistance cassette. To modulate GAT201 
expression, we similarly inserted promoter regions of CNAG_02044 (termed promoter 
A), CNAG_00456 (B), CNAG_03437 (C), or CNAG_07442 (D) upstream of that gene 
(cloning details available on request). The gat201Δ usv101Δ double mutant strain was 
made by crossing single mutants on V8 medium7. The rim101Δ usv101Δ and sp1Δ 
usv101Δ double mutants were generated by gene deletion (as above) into the 
usv101Δ mutant4. Plasmids for complementation and over-expression were checked by 
DNA sequencing and all transformants were confirmed by drug selection and PCR.  
 
Phenotyping 
To test mutant growth under various stress conditions, cells cultured overnight in YPD 
were collected by centrifugation, adjusted to 2 × 106 cells/ml in PBS, and three 10-fold 
serial dilutions were prepared. To test oxidative and nitrosative stress sensitivity, 5-µl 
aliquots of the original cell suspension and each dilution were spotted onto solid YNB 
medium (0.67% w/v yeast nitrogen base without amino acids, 2% w/v glucose, 2% w/v 
agar, 25 mM sodium succinate, pH 4.0) containing either 0.5 mM hydrogen peroxide 
(H2O2) or 0.5 mM sodium nitrite (NaNO2). For other studies, 5-µl aliquots were spotted 
onto solid YPD medium containing 1.2 M NaCl, 1.5 M sorbitol, 6% (v/v) ethanol, 0.01% 
(w/v) sodium dodecyl sulfate (SDS), 0.05% (w/v) Calcofluor white (Fluorescent 
Brightener 28), 0.05% (w/v) caffeine, or 50 mM Tris (pH 8.8).  
 To measure capsule thickness, cells were induced for capsule as described 
above. Capsules were then visualized by negative staining with India Ink and a 
minimum of 100 randomly chosen cells were imaged with identical acquisition settings 
on a Zeiss Axioskop 2 MOT Plus wide-field fluorescence microscope for measurement 
of capsule thickness.  
 To quantitate shed capsule, we induced capsule (as above) for 90 min, removed 
the cells by centrifugation, and measured the GXM content of the supernatant fraction 
by ELISA as in reference 8. To assess capsule monosaccharide composition, GXM was 
isolated from culture supernatant fractions and analyzed at the Complex Carbohydrate 
Research Center as in reference 9. 
 To assess shed melanin, cells were grown overnight in YPD, washed in water, 
resuspended at 106/ml in L-DOPA medium (per liter, 1 g L-asparagine, 1 g glucose, 3 g 
KH2PO4, 250 mg MgSO4-7H20, and 100 mg L-DOPA), and grown for 20 h at 30 °C with 
shaking (230 rpm). Triplicate samples were taken at 20 h, the cells pelleted, and the 
supernatant measured for OD475. To assess cell-associated melanin, cells were spotted 
on solid L-DOPA medium (above ingredients with 1 mg/ml thiamine and D-biotin). 
 
Macrophage uptake and survival 
Engulfment of cryptococcal cells by human THP-1 macrophages was measured as in 
reference10. Briefly, C. neoformans strains were either grown in YPD or induced for 
capsule for 24 h as described above, collected by centrifugation, washed in PBS, 
stained with Lucifer Yellow dye, and, in some experiments, opsonized with 40% human 
serum (from healthy volunteers, obtained following a protocol approved by the 
Washington University School of Medicine IRB). Fungi were adjusted to 106 cells/ml, 
added to adherent THP-1 cells in a 96-well plate, and incubated for 1 h at 37°C in a 5% 
CO2 atmosphere. Cells were fixed with 4% paraformaldehyde, stained with DAPI and 
CellMask™ Deep Red plasma membrane stain, and the plate was imaged on a Cytation 
3 Cell Imaging Multi Mode Reader (BioTek, Winooski, VT). Images were analyzed using 
the INCell Developer Toolbox (GE Healthcare) and the phagocytic index was calculated 
as ingested fungi per 100 macrophages. 
 To assess fungal survival within THP-1 macrophages, C. neoformans strains 
were grown overnight in YPD, washed in PBS, opsonized with 40% human serum, and 
3.5 x 104 cells added to 3.5 x 105 THP-1 macrophages per well in a 12-well plate. After 
a 1 h incubation the plate was washed thoroughly with PBS and incubated for various 
time periods before the addition of 1 ml of lysis buffer (0.05% w/v SDS, 1 mM EDTA in 
dH2O) per well. The lysate was diluted and plated on YPD agar to obtain CFUs.  
 
Blood-brain barrier transmigration assays 
To measure fungal traversal of the blood-brain barrier (BBB) we used in vitro model 
BBB as described in reference11. Briefly, 5 x 104 cells of the human cerebral 
microvascular endothelial cell line hCMEC/D3 were seeded on 12-well cell culture 
inserts (pore size 8 µm; BD Falcon, Corning) and grown to confluence (5 – 6 days), with 
media replaced on day 3. The integrity of the monolayer was monitored daily by 
measuring the transendothelial electrical resistance (TEER) with a EVOM2 
voltohmmeter (World Precision Instruments) and was typically around 80 ohms*cm2 at 
the day of the experiment. To assay transmigration, log-phase C. neoformans were 
washed twice in PBS and 108 cells were resuspended and incubated in 40% fresh 
human serum in PBS for 30 min. The cells were collected by centrifugation, 
resuspended at 2 x 106 cells/ml in migration media (RPMI containing 1% FBS), and 500 
µls were used to replace the medium above the model barrier; migration medium alone 
was used to replace the medium in the lower chamber. At various times TEER was 
measured to confirm barrier integrity and 1-ml aliquots were removed from the bottom 




Strains to be tested were cultured overnight in YPD medium, collected by centrifugation, 
washed in PBS, and diluted to 106 cells/ml in PBS for intranasal inoculation (50 µl) into 
4-6 week-old female A/Jcr mice (National Cancer Institute) that had been anesthetized 
with a combination of ketaset-HCl and xylazine. PBS alone was instilled as a control for 
histology (uninfected mice). Initial inocula were plated to confirm CFUs. To assess long-
term survival, ten infected animals were weighed 1 h post-infection and at least every 
other day afterwards. Mice were sacrificed if their weight fell below 80% of peak (an 
outcome which in this protocol precedes any signs of disease) or upon completion of 
the study.  
 To follow organ burden, 30 mice were inoculated with usv101Δ and 12 with wild-
type cells. The animals were weighed as above and three mice from each cohort were 
sacrificed every five days until completion of the study. If any mice fell to below 80% of 
peak weight, those animals were sacrificed, along with additional mice from the same 
group chosen at random to maintain a triplicate set. Lungs, brain, and spleen were 
harvested from all mice, homogenized in 5, 1, and 1 ml of PBS respectively, and serial 




For histology lungs were perfused with 10% formalin (Sigma HT501128) via the right 
ventricle, harvested and stored in the same solution for 24 hours, and then soaked 
sequentially in PBS, 30% ethanol, and 50% ethanol before transfer to 70% ethanol and 
submission to the Histology Core Facility of Washington University School of Medicine 
for processing, embedding, sectioning, and staining. 
 
Flow cytometry and cytokine analysis 
Mice were inoculated as above with the wild type strain, usv101Δ, or PBS as an 
uninfected control. At 5, 15, and 45 days post-infection mice were sacrificed humanely 
and the lungs harvested. Pulmonary leukocytes were isolated as described in 
reference12, adjusted to 5 x 106 cells/ml in PBS, and incubated with 10 µg/ml 
CD16/CD32 (Fc block™) (BD Biosciences, San Diego, CA) for 20 min at 4°C. They 
were then incubated in the dark for 20 min at 4 °C with a mixture of antibodies specific 
for CD19, CD11b, CD11c, CD14 (from BD Biosciences), and CD3, CD4, CD8a, and Gr-
1 (from BioLegend, San Diego, CA), conjugated with the following dyes, respectively: 
phycoerythrin (PE), allophycocyanin (APC), peridinin-chlorophyll protein (PerCP Cy5.5), 
APC Cy7, fluorescein isothiocyanate (FITC), PE Cy7, PE Cy5, and Brilliant Violet 421. 
Samples were washed twice with FACS buffer (2% fetal bovine serum, 0.05% NaN3 in 
PBS) fixed with 2% paraformaldehyde in PBS, and analyzed on an LSRII flow cytometer 
(Benton Dickinson, Franklin Lakes, NJ) with data interpreted using FlowJo software 
(Tree Star Inc., Ashland, OR). Lung neutrophils were designated as CD11b+ Gr1+ cells. 
 For pulmonary cytokine analysis, lungs were placed into 2 ml PBS supplemented 
with cOmplete protease inhibitor cocktail (Roche; 1 tablet/10 ml), homogenized, and 
spun at 10,000 x g for 15 min at 4°C. The supernatant fraction was removed and 50 µl 
of each sample was used for analyte capture with the Cytokine Mouse Magnetic 20-
Plex Panel Kit (Life Technologies). Cytokine levels were measured on the Luminex 100 
with xPONENT 3.1 software (EMD Millipore, Billerica, MA). 
 
RNA Isolation 
Prior to each experiment, cells were transferred from -80°C to YPD agar plates and 
grown for 3 days before streaking for isolation. Cells (three biological replicates per 
strain) were then cultured from single colonies overnight in YPD and shifted to capsule-
inducing conditions (DMEM, 37°C, 5% CO2) for the desired interval prior to isolation of 
total RNA. To prevent mRNA degradation, ice-cold stop solution (5% Tris-saturated 
phenol in ethanol) was added directly to the cultures (1% v/v) before the approximately 
2 x 108 cells were collected by centrifugation. The cells were suspended in TRIzol 
reagent and lysed by mechanical bead-beating at 4°C with 0.5-mm silica-zirconia beads 
for 3 min, followed by a 2-min rest on ice, for a total of 4 cycles. Following lysis, total 
RNA was extracted according to the manufacturer’s instructions. Residual DNA was 
removed from the RNA preparation with the TURBO DNA-free kit.  
 
RNA-seq library preparation and sequencing 
Samples were isolated for RNA-seq library preparation as in reference5. Briefly, poly (A) 
RNA was selected from total RNA with the mRNA Catcher Plus Kit using an epMotion 
5075 liquid handling robot (Eppendorf) and sheared by incubating in TURBO DNA-free 
buffer at 75 °C for 10 min. The samples were purified with the QIAquick PCR 
Purification Kit, and first strand cDNA synthesis was performed using random 
hexameric primers and SuperScript III Reverse Transcriptase, followed by treatment 
with E. coli DNA ligase, DNA polymerase I, and RNase H for second-strand synthesis 
using standard methods. The cDNA libraries were end-repaired with a Quick Blunting kit 
and A-tailed using Klenow exo- with dATP (New England Biolabs). Illumina adapters 
with four base barcodes were ligated to the cDNA and fragments ranging from 150-250 
bp in size were selected using gel electrophoresis. The libraries were enriched in a 10-
cycle PCR using Phusion Hot Start II High-Fidelity DNA (Fermentas), purified, and 
pooled in equimolar ratios for multiplex sequencing on an Illumina HiSeq 2500. 
 
RNA-seq design and data analysis 
Three biological replicates of each deletion mutant were profiled. To control for batch 
effects, a set of three wild type replicates was profiled with every batch of deletion 
mutants. The wild type replicate set was carried through the experimental stages, from 
induction to sequencing, at the same time as its matched mutant replicate sets. For all 
RNA-seq samples, the mean and median sequencing depth were 5.0 and 4.7 million 
reads respectively and the interquartile range of sequencing depth was 4.1 - 5.3 million 
reads. Sequenced reads were aligned to the C. neoformans H99 reference sequence 
v2 using TopHat version 2.0.413 and Bowtie version 0.12.814. Reads that aligned 
uniquely to the reference sequence were considered for gene expression quantification 
with Cufflinks version 2.0.215 and gene boundaries were defined by using version 2 of 
the C. neoformans genome annotation provided from the Broad institute. Gene 
expression was normalized using the Cufflinks option for upper-quartile normalization. 
After gene expression quantification, samples not passing the rigorous quality control 
filters described below were removed from consideration. Counts of reads mapping to 
each gene were quantitated using the htseq-count tool in version 0.5.3 of the HTSeq 
Python package16,17. Differential expression analysis comparing mutant and wild type 
expression profiles from matching conditions was performed using LIMMA17,18 with the 
voom transformation applied to read counts19. All mutant and wild type expression 
profile sets from the same condition that passed the quality control standards were used 
for differential expression analysis. To account for batch effects between r
a design matrix was constructed which considered batch and treatment effects. Genes 
were considered to have responded to the treatment factor if their q-value (false-
discovery rate) was ≤ 0.05.  
 
RNA-seq quality control  
The mean and median expression of USV101 in usv101Δ mutant expression profiles 
was 0.3% and 0% of USV101 wild type levels respectively. The low levels of expression 
that remained for some samples was likely the result of errors in the sequencing 
process itself, either due to contamination between samples or a low level of error in 
matching barcodes for multiplexed samples to reads. The mean and median expression 
of USV101 in USV101OE expression profiles was 801% and 844% of USV101 wild type 
levels respectively. In addition, within each replicate set the median of all genes’ 
coefficients of variation (CoV, the standard deviation divided by the mean) was required 
to be ≤ 0.2. Any replicate set which did not pass this CoV filter was not used for 
differential expression analysis, and the mutant expression profiles were remade. 
However, replicate sets were rescued if the median CoV could be lowered below 0.2 by 
removing an outlier expression profile replicate. 
 
Computational methods (detailed by Figure) 
Temporal expression of regulators of USV101, GAT201, and RIM101. 
To construct the network of regulators of USV101, GAT201, and RIM101 (Fig. 5A), we 
examined the 10,000 most confident predictions from our recently published network of 
capsule size regulators4. From among these, we selected the regulators that are 
required for normal capsule growth and are predicted to regulate USV101, GAT201, or 
RIM101. These regulators and the interactions among them are shown. For the cyclic 
AMP (cAMP) pathway, we combined the interactions involving Pkr1 (the repressive 
subunit of the heterotetrameric complex) and Cac1 (the adenylate cyclase catalytic 
subunit), keeping only those that were regulated in opposite directions by these two 
proteins.  
 
With each regulator node in the network diagram, we plotted the temporal expression 
pattern of the regulator in WT cells at 0, 1.5, 3, 8, and 24 h after transfer to capsule-
inducing conditions (reference4; GEO: GSE60398). Each plotted point is the median 
expression of the regulator at the indicated time in three RNA-seq replicates.  To allow 
for each temporal expression pattern to be displayed on the same scale, the temporal 
expression pattern of each regulator was normalized to the 0-1 range by subtracting its 
minimum expression value from expression value at each time point and then dividing 
by its maximum expression value. We computed the time-course for the cAMP node by 
identifying the targets of cAMP that are predicted to be both activated by Cac1 and 
repressed by Pkr1. We inferred a cAMP temporal expression pattern as the median 
temporal expression pattern of the cAMP targeted genes. 
 
Construction of the regulatory network map (Fig. 5B). 
To construct a network depicting the capsule-implicated putative direct functional 
targets of Usv101, we identified the capsule involved regulatory targets of Usv101 in 
capsule non-inducing conditions (a.k.a. 0 hours post-induction) and in capsule inducing 
conditions at 1.5 hours and 24 hours post-induction. First, to identify the functional 
targets of Usv101 in each condition, we compared wild type and usv101 mutant 
expression profiles from the same time point. Genes identified as differentially 
expressed (q-value ≤ 0.02) were considered functional targets of Usv101 at that time 
point. Next, the subset of functional targets of Usv101 at a given time point that are 
regulated directly by Usv101 were identified by intersecting the functional targets from 
each time point with a set of Usv101 direct physical targets. The set of Usv101 direct 
physical targets was defined as the union of 436 Usv101 ChIP-positive targets 
(reference4; GEO: GSE60398) and the top 20% of genes most likely to be bound by 
Usv101 according to binding potential estimates generated using the Usv101 position 
weight matrix (PWM) we inferred from our ChIP data (reference4, Supplemental File 5).  
To estimate the Usv101 binding potential on each gene’s promoter, FIMO20 was used to 
scan the Usv101 ChIP-inferred PWM over the promoter of each C. neoformans gene, 
with promoters defined as the 600 bases upstream of the start codon. Binding sites that 
were identified by FIMO at a P-value ≤ 0.005 were considered in subsequent analyses. 
Two models of binding were considered. For each TF, the strong site model ranks 
promoters containing one or more significant binding sites according to the negative log 
P-value of the most significant site. The weak site model ranks promoters containing 
one or more significant binding sites by the sum of the negative log P-values for all 
significant sites in a promoter. The final Usv101 binding potential score for each gene 
was computed using the geometric mean of the gene’s strong and weak site model 
Usv101 binding potential scores. 
 
Finally, only the 100 known capsule-implicated genes were considered for inclusion4. 
Therefore, at each time point, the known capsule-involved genes that are functional 
targets of Usv101, defined by differential expression analysis, and physical targets, 
defined by Usv101 ChIP support or PWM-based binding strength, are displayed. 
 
GAT201, RIM101, and SP1 expression.  
The expression levels of GAT201, RIM101, and SP1 in wild-type cells (Fig. 6A) were 
quantified by taking the median of the 3 replicates for the time-point in the time-course 
expression dataset (reference4; GEO: GSE60398).  The expression of GAT201 and 
RIM101 in usv101 mutants was quantified using RNA-seq expression profiles generated 
in this paper. Arbitrary units of gene expression were computed by dividing each RPKM 
gene expression value by 100,000.  
 
Characterization of Usv101 mRNA level and activity (Figure S2). 
The expression level of USV101 was quantified by using an RNA-seq time course of 
WT cells immediately before transfer from rich media into capsule-inducing conditions 
and at 1.5, 3, 8, and 24 h after transfer (reference4; GEO: GSE60398). At each time, the 
expression level of USV101 was computed as the median value of the three replicates. 
The expression profile of USV101 across the time course was normalized by dividing 
the expression of USV101 at each time point by the expression of USV101 at the 1.5 
hour time point.  
 
The activity of Usv101 was also investigated by quantifying the number of putative 
direct functional targets for Usv101 in the non-inducing condition (time 0) and at 1.5 and 
24 hours after transfer into capsule inducing conditions. At each time, the number of 
activated and repressed putative direct functional targets of Usv101 was determined by 
intersecting the ChIP-positive targets of Usv1014 with the genes whose expression was 
at least 2-fold down-regulated or up-regulated, respectively, in the usv101 mutant 
compared to wild type expression at the same time point. 
 
 
References for Supplementary Methods 
 
1 Nelson, R. T., Hua, J., Pryor, B. & Lodge, J. K. Identification of virulence mutants 
of the fungal pathogen Cryptococcus neoformans using signature-tagged 
mutagenesis. Genetics 157, 935-947 (2001). 
2 Fu, J., Hettler, E. & Wickes, B. L. Split marker transformation increases 
homologous integration frequency in Cryptococcus neoformans. Fungal Genet 
Biol 43, 200-212 (2006). 
3 Toffaletti, D. L., Rude, T. H., Johnston, S. A., Durack, D. T. & Perfect, J. R. Gene 
transfer in Cryptococcus neoformans by use of biolistic delivery of DNA. Journal 
of Bacteriology 175, 1405-1411 (1993). 
4 Maier, E. J. et al. Model-driven mapping of transcriptional networks reveals the 
circuitry and dynamics of virulence regulation. Genome Res 25, 690-700 (2015). 
5 Haynes, B. C. et al. Toward an integrated model of capsule regulation in 
Cryptococcus neoformans. PLoS Pathog 7, e1002411 (2011). 
6 Ory, J. J., Griffith, C. L. & Doering, T. L. An efficiently regulated promoter system 
for Cryptococcus neoformans utilizing the CTR4 promoter. Yeast 21, 919-926 
(2004). 
7 Kwon-Chung, K. J., Edman, C. & Wickes, B. L. Genetic association of mating 
types and virulence in Cryptococcus neoformans. Infect. Immun. 60, 602-605 
(1992). 
8 Percival, A., Thorkildson, P. & Kozel, T. R. Monoclonal antibodies specific for 
immunorecessive epitopes of glucuronoxylomannan, the major capsular 
polysaccharide of Cryptococcus neoformans, reduce serotype bias in an 
immunoassay for cryptococcal antigen. Clin Vaccine Immunol 18, 1292-1296 
(2011). 
9 Kumar, P. et al. Pbx proteins in Cryptococcus neoformans cell wall remodeling 
and capsule assembly. Eukaryot Cell 13, 560-571 (2014). 
10 Srikanta, D., Yang, M., Williams, M. & Doering, T. L. A sensitive high-throughput 
assay for evaluating host-pathogen interactions in Cryptococcus neoformans 
infection. PLoS One 6, e22773 (2011). 
11 Daniels, B. P. et al. Immortalized human cerebral microvascular endothelial cells 
maintain the properties of primary cells in an in vitro model of immune migration 
across the blood brain barrier. J Neurosci Methods 212, 173-179 (2013). 
12 Wozniak, K. L. & Levitz, S. M. Isolation and purification of antigenic components 
of Cryptococcus. Methods Mol Biol 470, 71-83 (2009). 
13 Trapnell, C., Pachter, L. & Salzberg, S. L. TopHat: discovering splice junctions 
with RNA-Seq. Bioinformatics 25, 1105-1111 (2009). 
14 Langmead, B., Trapnell, C., Pop, M. & Salzberg, S. L. Ultrafast and memory-
efficient alignment of short DNA sequences to the human genome. Genome Biol 
10, R25 (2009). 
15 Trapnell, C. et al. Transcript assembly and quantification by RNA-Seq reveals 
unannotated transcripts and isoform switching during cell differentiation. Nat 
Biotechnol 28, 511-515 (2010). 
16 Anders, S., Pyl, P. T. & Huber, W. HTSeq--a Python framework to work with 
high-throughput sequencing data. Bioinformatics 31, 166-169 (2015). 
17 Wettenhall, J. M. & Smyth, G. K. limmaGUI: a graphical user interface for linear 
modeling of microarray data. Bioinformatics 20, 3705-3706 (2004). 
18 Smyth, G. K. Linear models and empirical bayes methods for assessing 
differential expression in microarray experiments. Statistical applications in 
genetics and molecular biology 3, Article3 (2004). 
19 Law, C. W., Chen, Y., Shi, W. & Smyth, G. K. voom: Precision weights unlock 
linear model analysis tools for RNA-seq read counts. Genome Biol 15, R29 
(2014). 
20 Grant, C. E., Bailey, T. L. & Noble, W. S. FIMO: scanning for occurrences of a 
given motif. Bioinformatics 27, 1017-1018 (2011). 
 
